COMPANY

Theriva Biologics

HQ: Rockville, MD source · therivabio.com ↗ · Mid-Atlantic

Keywords: oncology cancer metastatic pancreatic cancer Irritable Bowel Syndrome With Constipation Enteritis Caused by Radiation (Disorder) Enteritis Caused by Radiation Clostridium Difficile Clostridium Infections SYN-004 SYN-010

Location: Rockville, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

$7.5MRaised (2 yrs)8Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Form D reports $13.11M, incl. warrant exercise value (filed Oct 24, 2025). SEC Form D 0001104659-25-101914 (Oct 24, 2025)
Evidence (1 event)
- Oct 24, 2025 · SEC Form D 0001104659-25-101914
  Name of Issuer: Theriva Biologics, Inc.; CIK: 894158; Address: Rockville, MD; Submission type: D; Filing date: 2025-10-24; Industry Group: Biotechnology; Date of First Sale: 2025-10-17; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 13109494; Total Amount Sold: 13109494; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Feb 18, 2026 Partnership Partnership / licensing: $300,000 (upfront, as published); deal value up to $38M (kept separate from upfront), announced Feb 18, 2026. Source: SEC filing. source ↗
May 8, 2025 Raise Follow-on offering: $7.5M (total, as published), announced May 8, 2025. Source: company release on GlobeNewswire. source ↗
Oct 18, 2021 Trial start Phase 1: Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020 source ↗
Mar 22, 2021 Trial start Phase 1: Pharmacokinetics, Safety, and Tolerability of SYN-020 source ↗
Feb 15, 2021 Trial start Phase 1/Phase 2: SYN-004 Safety and Tolerability in Allo-HCT Subjects source ↗
2015-10 Trial start Phase 2: A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C source ↗
2015-10 Trial start Phase 2: A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI source ↗
2015-06 Trial start Phase 2: A Study of the Effect of SYN-010 on Subjects With IBS-C source ↗
2015-06 Trial start Phase 1/Phase 2: A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy source ↗
2015-03 Trial start Phase 1/Phase 2: A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy source ↗

Upcoming milestones

Sep 30, 2029 (ESTIMATED) · Phase 1/Phase 2 · SYN-004 Safety and Tolerability in Allo-HCT Subjects · NCT04692181

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $7.5M. Last 2 years.

May 8, 2025 Follow-on offering: $7.5M (total, as published), announced May 8, 2025. Source: company release on GlobeNewswire. source ↗
Feb 18, 2026 Partnership / licensing: $300,000 (upfront, as published); deal value up to $38M (kept separate from upfront), announced Feb 18, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT04692181	SYN-004 Safety and Tolerability in Allo-HCT Subjects	Phase 1/Phase 2	Active, not recruiting	Feb 15, 2021	Sep 30, 2029 (estimated)
NCT04815993	Pharmacokinetics, Safety, and Tolerability of SYN-020	Phase 1	Completed	Mar 22, 2021	May 18, 2021 (actual)
NCT05045833	Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020	Phase 1	Completed	Oct 18, 2021	Feb 22, 2022 (actual)
NCT02495623	A Study of the Effect of SYN-010 on Subjects With IBS-C	Phase 2	Completed	2015-06	2015-10 (actual)
NCT02493036	A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C	Phase 2	Completed	2015-10	2015-12 (actual)
NCT02473640	A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy	Phase 1/Phase 2	Completed	2015-06	2016-04 (actual)
NCT02419001	A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy	Phase 1/Phase 2	Completed	2015-03	2015-09 (actual)
NCT02563106	A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI	Phase 2	Completed	2015-10	2016-11 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2025-10-24 Raise Private raise (SEC Form D): $13.1M sold; issuer “Theriva Biologics, Inc.”. Verified from the SEC filing. SEC filing ↗